Intellia Therapeutics (NTLA) EBT Margin Growth (3y) (2018 - 2026)
Intellia Therapeutics (NTLA) EBT Margin Growth (3y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 9,237.00 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 441.00 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -408.00 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 363.00 |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Intellia Therapeutics | 1.27 Bn | 1.27 Bn | - | -1,288.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,288.00 |
| Dec 31, 2025 | 39,886.00 |
| Sep 30, 2025 | 4,901.00 |
| Jun 30, 2025 | 62,069.00 |
| Mar 31, 2025 | 156,465.00 |
| Dec 31, 2024 | -34,433.00 |
| Sep 30, 2024 | 777,057.00 |
| Jun 30, 2024 | 1.39 Mn |
| Mar 31, 2024 | 668,318.00 |
| Dec 31, 2023 | 1.13 Mn |
| Sep 30, 2023 | -101,175.00 |
| Jun 30, 2023 | -88,476.00 |
| Mar 31, 2023 | -97,814.00 |
| Dec 31, 2022 | -52,576.00 |
| Sep 30, 2022 | -122,633.00 |
| Jun 30, 2022 | -108,495.00 |
| Mar 31, 2022 | -270,905.00 |
| Dec 31, 2021 | -39,587.00 |
| Sep 30, 2021 | -826,824.00 |
| Jun 30, 2021 | -1.48 Mn |